General Information:

Id: 2,897
Diseases: Breast cancer - [OMIM]
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
article
Reference: Alimova IN et al.(2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915 [PMID: 19221498]

Interaction Information:

Comment Metformin showed biological activity against all estrogen receptor (ER) positive and negative, erbB2 normal and abnormal breast cancer cell lines tested: MCF-7, MCF-7/713 (MCF-7 transfected with erbB2), BT-474 and SKBR-3.
Formal Description
Interaction-ID: 26599

drug/chemical compound

Metformin

decreases_activity of

disease

Breast cancer

Drugbank entries Show/Hide entries for Metformin
Comment Metformin inhibited cellular proliferation, reduced colony formation and caused partial cell cycle arrest at the G(1) checkpoint.
Formal Description
Interaction-ID: 26600

drug/chemical compound

Metformin

decreases_activity of

Drugbank entries Show/Hide entries for Metformin
Comment Metformin inhibited cellular proliferation, reduced colony formation and caused partial cell cycle arrest at the G(1) checkpoint.
Formal Description
Interaction-ID: 26601

drug/chemical compound

Metformin

increases_activity of

Drugbank entries Show/Hide entries for Metformin
Comment Metformin did not induce apoptosis (as measured by DNA fragmentation and PARP cleavage) in luminal A, B or erbB2 subtype breast cancer cell lines.
Formal Description
Interaction-ID: 26602

drug/chemical compound

Metformin

NOT increases_activity of

Drugbank entries Show/Hide entries for Metformin
Comment The expression of erbB2 protein and activated erbB2 (P-erbB2) were each reduced by metformin, particularly in those lines with the highest levels of erbB2 expression.
Formal Description
Interaction-ID: 26603

drug/chemical compound

Metformin

decreases_expression of

gene/protein

ERBB2

Drugbank entries Show/Hide entries for Metformin or ERBB2
Comment Metformin treatment also resulted in significant reductions in the activation (phosphorylation) of mitogen-activated protein kinase (MAPK) but not MAPK expression. Similarly, Akt activation (P-Akt) was significantly reduced in each of the 4 lines, although Akt protein expression was only modestly reduced. The levels of mTOR and P-mTOR were decreased as well, although the magnitude of these changes was not as significant as changes in the proteins listed above.
Formal Description
Interaction-ID: 26609

drug/chemical compound

Metformin

decreases_activity of

gene/protein

MAPK1

Drugbank entries Show/Hide entries for Metformin or MAPK1
Comment Metformin treatment also resulted in significant reductions in the activation (phosphorylation) of mitogen-activated protein kinase (MAPK) but not MAPK expression. Similarly, Akt activation (P-Akt) was significantly reduced in each of the 4 lines, although Akt protein expression was only modestly reduced. The levels of mTOR and P-mTOR were decreased as well, although the magnitude of these changes was not as significant as changes in the proteins listed above.
Formal Description
Interaction-ID: 26610

drug/chemical compound

Metformin

decreases_activity of

gene/protein

AKT1

Drugbank entries Show/Hide entries for Metformin or AKT1
Comment Metformin treatment also resulted in significant reductions in the activation (phosphorylation) of mitogen-activated protein kinase (MAPK) but not MAPK expression. Similarly, Akt activation (P-Akt) was significantly reduced in each of the 4 lines, although Akt protein expression was only modestly reduced. The levels of mTOR and P-mTOR were decreased as well, although the magnitude of these changes was not as significant as changes in the proteins listed above.
Formal Description
Interaction-ID: 26611

drug/chemical compound

Metformin

NOT decreases_expression of

gene/protein

MAPK1

Drugbank entries Show/Hide entries for Metformin or MAPK1
Comment Metformin treatment also resulted in significant reductions in the activation (phosphorylation) of mitogen-activated protein kinase (MAPK) but not MAPK expression. Similarly, Akt activation (P-Akt) was significantly reduced in each of the 4 lines, although Akt protein expression was only modestly reduced. The levels of mTOR and P-mTOR were decreased as well, although the magnitude of these changes was not as significant as changes in the proteins listed above.
Formal Description
Interaction-ID: 26612

drug/chemical compound

Metformin

decreases_activity of

gene/protein

MTOR

Drugbank entries Show/Hide entries for Metformin or MTOR
Comment At the molecular level, metformin treatment was associated with a reduction of cyclin D1 and E2F1 expression with no changes in p27(kip1) or p21(waf1).
Formal Description
Interaction-ID: 26617

drug/chemical compound

Metformin

decreases_expression of

gene/protein

CCND1

Drugbank entries Show/Hide entries for Metformin or CCND1
Comment At the molecular level, metformin treatment was associated with a reduction of cyclin D1 and E2F1 expression with no changes in p27(kip1) or p21(waf1).
Formal Description
Interaction-ID: 26618

drug/chemical compound

Metformin

decreases_expression of

gene/protein

E2F1

Drugbank entries Show/Hide entries for Metformin
Comment At the molecular level, metformin treatment was associated with a reduction of cyclin D1 and E2F1 expression with no changes in p27(kip1) or p21(waf1).
Formal Description
Interaction-ID: 26620

drug/chemical compound

Metformin

NOT affects_expression of

gene/protein

CDKN1B

Drugbank entries Show/Hide entries for Metformin
Comment At the molecular level, metformin treatment was associated with a reduction of cyclin D1 and E2F1 expression with no changes in p27(kip1) or p21(waf1).
Formal Description
Interaction-ID: 26621

drug/chemical compound

Metformin

NOT affects_expression of

gene/protein

CDKN1A

Drugbank entries Show/Hide entries for Metformin
Comment Within the therapeutic dosage range for type II diabetes, metformin inhibited erbB2 tyrosine kinase activity and downstream signaling. These data suggest that metformin may have anti-cancer activity involving important signaling pathways-beyond its effects on insulin and insulin-like growth factor associated mitogenesis.
Formal Description
Interaction-ID: 26623

drug/chemical compound

Metformin

decreases_activity of

gene/protein

ERBB2

Drugbank entries Show/Hide entries for Metformin or ERBB2
Comment Within the therapeutic dosage range for type II diabetes, metformin inhibited erbB2 tyrosine kinase activity and downstream signaling. These data suggest that metformin may have anti-cancer activity involving important signaling pathways-beyond its effects on insulin and insulin-like growth factor associated mitogenesis.
Formal Description
Interaction-ID: 26624

drug/chemical compound

Metformin

decreases_activity of

process

ERBB2 signaling pathway

Drugbank entries Show/Hide entries for Metformin